Q1 FY27 Results: Revenue down 2% YoY, PAT drops 43% YoY

Revenue DeclineEbitda Margin CompressionResults View source PDF Explain this filing

TRANSPEK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.4%Reaction day

₹1269.30

prior close

₹1222.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-4.4% vs market

Commodity Chemicals peers, median of 54sector-0.2%-4.3% vs sector

On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 4.3 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-0.2

15m

+0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.4-0.1-4.4-0.2-4.3

Next day

-5.5-0.2-5.2-1.3-4.2

-7.8+0.1-8.0-1.3-6.5

-8.5+0.3-8.8-0.7-7.7

-11.8+0.4-12.1-0.6-11.2

-8.2+0.5-8.7-1.5-6.8

-6.3+0.3-6.6-2.8-3.5

15d

+13.4+1.9+11.5-1.5+14.9

+1.8+2.2-0.4+1.1+0.7

+6.4-1.2+7.5-1.0+7.3

—————

UpDownMarket · Nifty Microcap 250Sector · Commodity Chemicals peers, median of 54Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Transpek Industry reported Q1 FY27 standalone revenue of Rs 15,106.27 lakhs, down 2% YoY from Rs 15,423.32 lakhs. Net profit fell sharply to Rs 892.87 lakhs from Rs 1,558.11 lakhs, a 43% YoY decline. Other income also dropped to Rs 400.08 lakhs from Rs 1,166.13 lakhs. Sequentially, both revenue and profit improved from Q4 FY26. EPS stood at Rs 15.99 versus Rs 27.90 YoY. Auditor Bansi S. Mehta and Co. issued an unqualified review report with no qualifications.

Likely market impact

Weak YoY performance with sharp profit decline despite sequential improvement. Margin pressure from lower other income and higher costs may concern investors.